Transient immune-mediated agranulocytosis following<i>Mycoplasma pneumoniae</i>infection

Barge, Luani; Pahn, Gail; Weber, Nicholas

doi:10.1136/bcr-2018-224537

Cited by 5 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed that Mycoplasma in the lung increased significantly in the COPD model group compared with the control group while decreased significantly after QBPF intervention. Mycoplasma is a notable species traditionally associated with infection [ 80 ], and Mycoplasma pneumonia is a common respiratory pathogen [ 81 ]. Rikenellaceae_RC9_gut_group in the lung decreased significantly in the COPD model group compared with the control group while increased significantly after QBPF intervention.…”

Section: Discussionmentioning

confidence: 99%

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

Jia

et al. 2022

J Transl Med

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD), a prevalent, progressive respiratory disease, has become the third leading cause of death globally. Increasing evidence suggests that intestinal and pulmonary microbiota dysbiosis is associated with COPD. Researchers have shown that T helper (Th) 17/regulatory T (Treg) imbalance is involved in COPD. Qibai Pingfei Capsule (QBPF) is a traditional Chinese medicine used to treat COPD clinically in China. However, the effects of QBPF intervention on the Th17/Treg balance and microbiota in the gut and lung are still poorly understood. Methods This study divided the rats into three groups (n = 8): control, model, and QBPF group. After establishing the model of COPD for four weeks and administering of QBPF for two weeks, Th17 cells, Treg cells, their associated cytokines, transcription factors, and intestinal and pulmonary microbiota of rats were analyzed. Furthermore, the correlations between intestinal and pulmonary microbiota and between bacterial genera and pulmonary function and immune function were measured. Results The results revealed that QBPF could improve pulmonary function and contribute to the new balance of Th17/Treg in COPD rats. Meanwhile, QBPF treatment could regulate the composition of intestinal and pulmonary microbiota and improve community structure in COPD rats, suppressing the relative abundance of Coprococcus_2, Prevotella_9, and Blautia in the gut and Mycoplasma in the lung, but accumulating the relative abundance of Prevotellaceae_UCG_003 in the gut and Rikenellaceae_RC9_gut_group in the lung. Additionally, gut–lung axis was confirmed by the significant correlations between the intestinal and pulmonary microbiota. Functional analysis of microbiota showed amino acid metabolism was altered in COPD rats in the gut and lung. Spearman correlation analysis further enriched the relationship between the microbiota in the gut and lung and pulmonary function and immune function in COPD model rats. Conclusions Our study indicated that the therapeutic effects of QBPF may be achieved by maintaining the immune cell balance and regulating the gut-lung axis microbiota, providing references to explore the potential biomarkers of COPD and the possible mechanism of QBPF to treat COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

Jia

et al. 2022

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Our results showed that Mycoplasma in the lung increased significantly in the COPD model group compared with the control group while decreased significantly after QBPF intervention. Mycoplasma is a notable species traditionally associated with infection [85], and Mycoplasma pneumonia is a common respiratory pathogen [86]. Rikenellaceae_RC9_gut_group in the lung decreased significantly in the COPD model group compared with the control group while increased significantly after QBPF intervention.…”

Section: There Exists Regulation Of Qbpf In Immune Homeostasis and In...mentioning

confidence: 99%

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17 / Treg balance and gut-lung axis microbiota

Jia

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD), a prevalent, progressive respiratory disease, has become the third leading cause of death globally. Increasing evidence suggests that intestinal and pulmonary microbiota dysbiosis is associated with COPD. Researchers have shown that T helper (Th) 17/regulatory T (Treg) imbalance is involved in COPD. Qibai Pingfei Capsule (QBPF) is a traditional Chinese medicine used to treat COPD clinically in China. However, the effects of QBPF intervention on the Th17/Treg balance and microbiota in the gut and lung are still poorly understood. Methods: This study divided the rats into three groups (n=8): control, model, and QBPF group. After establishing the model of COPD for four weeks and administration of QBPF for two weeks, Th17 cells, Treg cells, their associated cytokines, transcription factors, and intestinal and pulmonary microbiota of rats were analyzed. Furthermore, the correlations between intestinal and pulmonary microbiota and between bacterial genera and pulmonary function and immune function were measured. Results: The results revealed that QBPF could improve pulmonary function and contribute to the new balance of Th17/Treg in COPD rats. Meanwhile, QBPF treatment could regulate the composition of intestinal and pulmonary microbiota and improve community structure in COPD rats, suppressing the relative abundance of Coprococcus_2 , Prevotella_9 , and Blautia in the gut and Mycoplasma in the lung, but accumulating the relative abundance of Prevotellaceae_UCG_003 in the gut and Rikenellaceae_RC9_gut_group in the lung. Additionally, gut–lung axis was confirmed by the significant correlations between the intestinal and pulmonary microbiota. Functional analysis of microbiota showed amino acid metabolism was altered in COPD rats in the gut and lung. Spearman correlation analysis further enriched the relationship between the microbiota in the gut and lung and pulmonary function and immune function in COPD model rats. Conclusions: Our study indicated that the therapeutic effects of QBPF may be achieved by maintaining the immune cell balance and regulating the gut-lung axis microbiota, providing references to explore the potential biomarkers of COPD and the possible mechanism of QBPF to treat COPD.

show abstract

“…In recent years, MMP accounts for 10%-40% of community acquired pneumonia (CAP) in children, especially in Asia [1]. If the host cannot effectively clear the pathogen of mycoplasma pneumoniae, immune response will continuously damage of the respiratory epithelium and cilia [2,3]. In addition, drug resistant MP strains are more and more common.…”

Section: Introductionmentioning

confidence: 99%

“…populationA total of 233 MMP pediatric patients were included in the study, with 121 males and 112 females, aged 4.541(1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14) years. Among them, 84 pediatric patients were diagnosed as SMPP, with the incidence of 36.1% (95% CI 29.9%-42.6%).…”

mentioning

confidence: 99%

Prediction Model for Severe Mycoplasma pneumoniae Pneumonia in Pediatric Patients by Admission Laboratory Indicators

Chang

Chen

et al. 2022

Journal of Tropical Pediatrics

View full text Add to dashboard Cite

Objective The purpose of this study was to develop a model for predicting severe Mycoplasma pneumoniae pneumonia (SMPP) in pediatric patients with Mycoplasma pneumoniae pneumonia (MPP) on admission by laboratory indicators. Methods Pediatric patients with MPP from January 2019 to December 2020 in our hospital were enrolled in this study. SMPP was diagnosed according to guideline for diagnosis and treatment of community-acquired pneumonia in children (2019 version). Prediction model was developed according to the admission laboratory indicators. Receiver operating characteristic curve and Goodness-of-fit test were analyzed for the predictive value. Results A total of 233 MPP patients were included in the study, with 121 males and 112 females, aged 4.541 (1–14) years. Among them, 84 (36.1%, 95% CI 29.9–42.6%) pediatric patients were diagnosed as SMPP. Some admission laboratory indicators (immunoglobulins M (IgM), eosinophil proportion, eosinophil count, hemoglobin, erythrocyte sedimentation rate (ESR), total protein, albumin and prealbumin) were found statistically different (p < 0.05) between non-SMPP group and SMPP group. Logistic regress analysis showed IgM, eosinophil proportion, eosinophil count, ESR and prealbumin were independent risk factors for SMPP. According to these five admission laboratory indicators, the prediction model for SMPP in pediatric patients was developed. The area under curve of the prediction model was 0.777, and the goodness-of-fit test showed that the predicted SMPP incidence by the model was consistent with the actual incidence (χ2 = 244.51, p = 0.203). Conclusion We developed a model for predicting SMPP in pediatric patients by admission laboratory indicators. This model has good discrimination and calibration, which provides a basis for the early identification SMPP on admission. However, this model should be validated by multicenter studies with large sample.

show abstract

Transient immune-mediated agranulocytosis followingMycoplasma pneumoniaeinfection

Cited by 5 publications

References 13 publications

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17 / Treg balance and gut-lung axis microbiota

Prediction Model for Severe Mycoplasma pneumoniae Pneumonia in Pediatric Patients by Admission Laboratory Indicators

Contact Info

Product

Resources

About